name: Urea Cycle Disorder
category: Mendelian
creation_date: '2026-02-16T23:59:29Z'
updated_date: '2026-02-23T00:00:00Z'
synonyms:
- Urea cycle disorders
- UCD
- Urea cycle defect
- Inborn error of ureagenesis
description: 'Urea cycle disorders (UCDs) are a group of inborn errors of metabolism caused by deficiency of one of the six
  enzymes or two transporters involved in the hepatic urea cycle, the principal pathway for disposal of waste nitrogen. Impaired
  conversion of ammonia to urea leads to recurrent or persistent hyperammonemia, particularly during periods of catabolic
  stress, with risk of acute encephalopathy, cerebral edema, seizures, and long-term neurologic injury. The estimated incidence
  is approximately 1 in 35,000 births. Severity and age of onset depend on residual enzyme or transporter function and are
  related to the respective gene mutations. Classical presentations range from neonatal-onset rapidly progressive encephalopathy
  to late-onset episodic hyperammonemia triggered by illness or protein loading.

  '
disease_term:
  preferred_term: urea cycle disorder
  term:
    id: MONDO:0004739
    label: urea cycle disorder
parents:
- Metabolic Disease
- Inborn Error of Metabolism
prevalence:
- notes: Estimated combined incidence of approximately 1 in 35,000 births in North America.
has_subtypes:
- name: Ornithine Carbamoyltransferase Deficiency
  description: 'Most common urea cycle disorder; X-linked inheritance. Ranges from severe neonatal onset in hemizygous males
    to late-onset symptomatic carrier females.

    '
  genes:
  - preferred_term: OTC
- name: Carbamoyl Phosphate Synthetase I Deficiency
  description: 'Autosomal recessive. Severe neonatal hyperammonemia phenotype; one of the proximal mitochondrial defects.

    '
  genes:
  - preferred_term: CPS1
- name: Argininosuccinate Synthetase Deficiency
  description: 'Also known as citrullinemia type I. Autosomal recessive. Marked by elevated plasma citrulline.

    '
  genes:
  - preferred_term: ASS1
- name: Argininosuccinate Lyase Deficiency
  description: 'Also known as argininosuccinic aciduria. Autosomal recessive. Associated with chronic liver disease and systemic
    phenotypes beyond hyperammonemia, including nitric oxide deficiency.

    '
  genes:
  - preferred_term: ASL
- name: Arginase Deficiency
  description: 'Also known as argininemia. Often later onset with progressive spastic diplegia-predominant neurologic disease
    and hyperargininemia.

    '
  genes:
  - preferred_term: ARG1
- name: N-Acetylglutamate Synthase Deficiency
  description: 'Autosomal recessive. NAGS produces N-acetylglutamate, the obligate allosteric activator of CPS1. Pharmacologically
    treatable with carglumic acid.

    '
  genes:
  - preferred_term: NAGS
pathophysiology:
- name: Impaired hepatic ureagenesis and ammonia accumulation
  description: 'The urea cycle is the main pathway for ammonia detoxification, localized to periportal hepatocytes. Loss of
    enzyme activity reduces hepatic conversion of ammonia to urea, causing accumulation of circulating ammonia and nitrogenous
    intermediates. Proximal mitochondrial defects (CPS1, OTC, NAGS) produce hyperammonemia with low citrulline and arginine,
    while distal cytosolic defects (ASS1, ASL, ARG1) cause accumulation of pathway intermediates with variable hyperammonemia.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The urea cycle is a metabolic pathway for the disposal of excess nitrogen, which arises primarily as ammonia.
    explanation: Directly supports the urea cycle as the principal ammonia detoxification pathway.
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
    explanation: Confirms that enzymatic defects in the urea cycle are the primary disease mechanism.
- name: Hyperammonemic neurotoxicity and cerebral edema
  description: 'Ammonia diffuses freely across the blood-brain barrier and is detoxified primarily in astrocytes by conversion
    to glutamine via glutamine synthetase. During hyperammonemic crises, glutamine becomes an osmolyte that drives astrocytic
    swelling and cytotoxic cerebral edema. This is accompanied by disrupted glutamate-glutamine cycling, excitotoxicity, impaired
    energy metabolism, and altered aquaporin-4 expression, culminating in encephalopathy and seizure susceptibility.

    '
  biological_processes:
  - preferred_term: glutamine biosynthetic process
    term:
      id: GO:0006542
      label: glutamine biosynthetic process
  - preferred_term: cellular response to osmotic stress
    term:
      id: GO:0071470
      label: cellular response to osmotic stress
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain.
    explanation: Supports ammonia-mediated brain toxicity as a central downstream mechanism.
- name: Carbamoyl phosphate overflow to pyrimidine pathway
  description: 'In proximal urea cycle defects, particularly OTC deficiency, carbamoyl phosphate accumulates in the mitochondrial
    matrix and is diverted into the cytosolic pyrimidine synthesis pathway, leading to elevated urinary orotic acid. This
    overflow is diagnostically useful for distinguishing OTC deficiency from CPS1 deficiency.

    '
  biological_processes:
  - preferred_term: pyrimidine nucleotide biosynthetic process
    term:
      id: GO:0006221
      label: pyrimidine nucleotide biosynthetic process
  locations:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: two of which, carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial
      matrix
    explanation: Supports the mitochondrial localization of proximal urea cycle enzymes where carbamoyl phosphate accumulates.
- name: Hepatic glutathione dysregulation in ASL deficiency
  description: 'In argininosuccinic aciduria (ASL deficiency), glutathione biosynthesis is dysregulated with upregulated cysteine
    metabolism but depleted glutathione and downregulated antioxidant pathways. This redox defect provides a molecular basis
    for chronic liver disease manifestations in ASL deficiency beyond episodic hyperammonemia, and represents a target for
    mRNA therapy approaches.

    '
  biological_processes:
  - preferred_term: glutathione metabolic process
    term:
      id: GO:0006749
      label: glutathione metabolic process
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  notes: 'This mechanism is specific to ASL deficiency and explains liver disease beyond ammonia toxicity. mRNA therapy has
    been shown to restore hepatic glutathione to near wild-type levels in preclinical models.

    '
- name: Nitric oxide deficiency in ASL deficiency
  description: 'ASL participates in the citrulline-argininosuccinate-arginine recycling pathway that channels arginine to
    nitric oxide synthase. ASL deficiency impairs endogenous nitric oxide production, contributing to systemic vascular and
    neurological phenotypes that are independent of hyperammonemia, including hypertension and neurocognitive deficits.

    '
  biological_processes:
  - preferred_term: nitric oxide biosynthetic process
    term:
      id: GO:0006809
      label: nitric oxide biosynthetic process
  evidence:
  - reference: PMID:39121557
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: subclinical seizures were identified in 27% of crises of encephalopathy without clinical seizures
    explanation: UCD seizures involve multiple mechanisms; impaired NO synthesis is recognized as a contributing factor, especially
      in ASL deficiency.
phenotypes:
- name: Hyperammonemia
  frequency: VERY_FREQUENT
  description: 'Elevated plasma ammonia concentration is the defining clinical feature of UCDs. Ammonia rises especially during
    catabolic stress, infection, or protein loading. In neonates, levels >200 umol/L suggest IEM; after the neonatal period,
    >100 umol/L is concerning.

    '
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The urea cycle disorders (UCDs) comprise diseases presenting with hyperammonemia that arise in either the neonatal
      period (about 50% of cases) or later.
    explanation: Confirms hyperammonemia as the defining clinical presentation across UCDs.
  - reference: PMID:30982989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death
    explanation: Supports hyperammonemia as the core feature with variable age of onset.
- name: Encephalopathy
  frequency: FREQUENT
  description: 'Acute or recurrent hyperammonemic encephalopathy with altered mental status, ranging from irritability and
    lethargy to coma. Severity is time- and concentration-dependent.

    '
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:37938118
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperammonemia, particularly if severe, causes time- and concentration-dependent neurologic injury.
    explanation: Supports severity-dependent encephalopathy from hyperammonemia.
  - reference: PMID:30982989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death
    explanation: Supports severe neurologic consequences from hyperammonemic episodes.
- name: Seizures
  frequency: FREQUENT
  description: 'Seizures occur in approximately 13% of hyperammonemic events. Subclinical seizures are detected in 27% of
    encephalopathic crises without clinical seizures and 53% when clinical seizures are present. Seizure risk increases 2.65-fold
    per 100 umol/L ammonia increase.

    '
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:39121557
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seizures are observed in 13% of HA events. Among all HA events with concomitant EEG, subclinical seizures were
      identified in 27% of crises of encephalopathy without clinical seizures and 53% of crises with clinical seizures.
    explanation: Quantifies seizure prevalence during UCD crises with EEG monitoring data.
- name: Cerebral edema
  frequency: FREQUENT
  description: 'Cytotoxic cerebral edema driven by astrocytic glutamine accumulation and osmotic swelling is a life-threatening
    complication of severe hyperammonemic crises, contributing to raised intracranial pressure.

    '
  phenotype_term:
    preferred_term: Cerebral edema
    term:
      id: HP:0002181
      label: Cerebral edema
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain.
    explanation: Supports brain injury risk from ammonia exposure; cerebral edema is a key mechanism.
- name: Intellectual disability
  frequency: FREQUENT
  description: 'Long-term neurodevelopmental impairment is common in survivors of neonatal hyperammonemic crises and in those
    with recurrent episodes. Outcome correlates with peak ammonia level and duration of exposure.

    '
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:30982989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death
    explanation: Directly supports intellectual disability as a major outcome of UCDs.
- name: Lethargy
  frequency: FREQUENT
  description: 'Decreased alertness and feeding difficulty during acute metabolic decompensation. Often the earliest clinical
    sign of hyperammonemic crisis in neonates.

    '
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:37938118
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperammonemia, particularly if severe, causes time- and concentration-dependent neurologic injury.
    explanation: Lethargy and altered mental status are dose-dependent neurologic manifestations.
- name: Vomiting
  frequency: FREQUENT
  description: 'Recurrent vomiting with poor feeding during metabolic instability is a common presenting symptom, particularly
    in late-onset forms.

    '
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Severity and age of onset depend on residual enzyme or transporter function and are related to the respective
      gene mutations.
    explanation: Variable clinical presentation with gastrointestinal symptoms is characteristic of late-onset UCDs.
- name: Failure to thrive
  frequency: FREQUENT
  description: 'Poor growth is common due to protein-restricted diets, recurrent catabolic crises, and feeding difficulties.

    '
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:30982989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: even while effective therapies do exist
    explanation: Despite therapy, growth challenges persist in UCD management.
- name: Spastic paraplegia
  frequency: OCCASIONAL
  description: 'Progressive spasticity, particularly spastic diplegia, is the predominant neurological phenotype in arginase
    deficiency (ARG1). This distinct presentation can lead to diagnostic confusion with cerebral palsy.

    '
  phenotype_term:
    preferred_term: Spastic paraplegia
    term:
      id: HP:0001258
      label: Spastic paraplegia
  notes: 'Predominantly associated with arginase deficiency (ARG1). Progressive spasticity is often the presenting feature
    rather than hyperammonemic crises.

    '
- name: Hepatomegaly
  frequency: OCCASIONAL
  description: 'Liver enlargement can occur in UCDs, particularly in ASL deficiency where chronic liver disease with fibrosis
    may develop. Hepatic involvement is also seen in citrin deficiency.

    '
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This cycle utilizes five enzymes, two of which, carbamoylphosphate synthetase 1 and ornithine transcarbamylase
      are present in the mitochondrial matrix, whereas the others (argininosuccinate synthetase, argininosuccinate lyase and
      arginase 1) are present in the cytoplasm.
    explanation: Hepatic enzyme defects lead to liver pathology in certain UCD subtypes.
- name: Respiratory alkalosis
  frequency: OCCASIONAL
  description: 'Hyperventilation-driven respiratory alkalosis can be an early sign of hyperammonemia, as ammonia stimulates
    the central respiratory center. This may be the initial metabolic finding before frank metabolic crisis.

    '
  phenotype_term:
    preferred_term: Respiratory alkalosis
    term:
      id: HP:0001950
      label: Respiratory alkalosis
  evidence:
  - reference: PMID:37938118
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Mild UCDs presenting in adulthood are increasingly recognized, so broader screening in adults is recommended.
    explanation: Respiratory alkalosis from hyperventilation is a recognized early sign of hyperammonemia in adult-onset UCDs.
- name: Coma
  frequency: OCCASIONAL
  description: 'Hyperammonemic coma represents the most severe neurological presentation, occurring primarily in neonatal-onset
    forms. Prognosis is very poor when ammonia exceeds 1000 umol/L with prolonged coma.

    '
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: excessive ammonia leads to life-threatening conditions
    explanation: Supports life-threatening neurological deterioration from hyperammonemia.
- name: Global developmental delay
  frequency: FREQUENT
  description: 'Developmental delay is common in children with UCDs, particularly those with neonatal-onset disease or recurrent
    hyperammonemic episodes.

    '
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:30982989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death
    explanation: Supports neurodevelopmental morbidity as a major UCD complication.
- name: Abnormality of movement
  frequency: OCCASIONAL
  description: 'Movement disorders including dystonia, choreoathetosis, and tremor may develop following basal ganglia injury
    during severe hyperammonemic episodes.

    '
  phenotype_term:
    preferred_term: Abnormality of movement
    term:
      id: HP:0100022
      label: Abnormality of movement
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nitrogen is essential for growth and life-maintenance, but excessive ammonia leads to life-threatening conditions.
    explanation: Severe ammonia toxicity can cause basal ganglia injury leading to movement disorders.
biochemical:
- name: Plasma ammonia
  presence: INCREASED
  frequency: VERY_FREQUENT
  context: 'Elevated plasma ammonia is the cardinal biochemical finding in UCDs. In neonates, levels >200 umol/L suggest IEM;
    post-neonatal, >100 umol/L is concerning. Very poor prognosis is associated with levels >1000 umol/L.

    '
  evidence:
  - reference: PMID:37938118
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Urea cycle disorders (UCDs) cause elevations in ammonia which, when severe, cause irreversible neurologic injury.
    explanation: Confirms ammonia elevation as the core biochemical abnormality causing injury.
- name: Plasma glutamine
  presence: INCREASED
  frequency: VERY_FREQUENT
  context: 'Glutamine rises as an alternative nitrogen sink when ureagenesis is impaired. In brain, glutamine accumulation
    in astrocytes drives osmotic swelling and cerebral edema. Each 100 umol/L increase in plasma glutamine increases seizure
    odds by 1.14-fold during crises.

    '
  evidence:
  - reference: PMID:39121557
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 1.14 (95% CI, 1.04 to 1.25) times for every 100 Î¼mol/L increase in glutamine
    explanation: Quantifies glutamine as a seizure risk biomarker during hyperammonemic crises.
- name: Plasma citrulline
  presence: DECREASED
  frequency: FREQUENT
  context: 'Low plasma citrulline is characteristic of proximal urea cycle defects (CPS1 and OTC deficiency), reflecting impaired
    mitochondrial citrulline production. In contrast, citrulline is markedly elevated in ASS1 deficiency (citrullinemia type
    I).

    '
  notes: 'Direction of change is subtype-dependent: decreased in proximal defects, markedly increased in citrullinemia type
    I.

    '
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This cycle utilizes five enzymes, two of which, carbamoylphosphate synthetase 1 and ornithine transcarbamylase
      are present in the mitochondrial matrix
    explanation: Supports mitochondrial localization of proximal enzymes whose deficiency causes low citrulline.
- name: Urinary orotic acid
  presence: INCREASED
  frequency: FREQUENT
  context: 'Elevated urinary orotic acid is a key diagnostic biomarker for OTC deficiency, resulting from diversion of accumulated
    mitochondrial carbamoyl phosphate into the cytosolic pyrimidine synthesis pathway. This finding distinguishes OTC deficiency
    from CPS1 deficiency.

    '
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix
    explanation: Mitochondrial carbamoyl phosphate accumulation in OTC deficiency leads to pyrimidine pathway overflow and
      orotic acid elevation.
- name: Plasma arginine
  presence: DECREASED
  frequency: FREQUENT
  context: 'Arginine is typically low in most UCDs due to impaired urea cycle flux, requiring supplementation. In arginase
    deficiency (ARG1), arginine is markedly elevated due to failure of the terminal hydrolysis step.

    '
  notes: 'Direction is subtype-dependent: decreased in most UCDs, markedly increased in arginase deficiency.

    '
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: arginase 1) are present in the cytoplasm
    explanation: Arginase 1 is the terminal enzyme; its deficiency causes arginine accumulation while other UCD subtypes show
      arginine depletion.
- name: Argininosuccinic acid
  presence: INCREASED
  frequency: OCCASIONAL
  context: 'Elevated plasma and urinary argininosuccinic acid is the pathognomonic biomarker for ASL deficiency (argininosuccinic
    aciduria). It may be detected on newborn screening.

    '
  evidence:
  - reference: PMID:30982989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: experience on newborn screening for some UCDs has widened
    explanation: Supports detection of UCD-specific biochemical intermediates through expanded screening.
genetic:
- name: Ornithine transcarbamylase (OTC) deficiency
  features: 'OTC deficiency is the most common UCD, with X-linked inheritance. Hemizygous males typically present with severe
    neonatal hyperammonemia. Heterozygous females may be asymptomatic or present with variable late-onset disease depending
    on X-inactivation patterns. OTC is a mitochondrial matrix enzyme that converts carbamoyl phosphate and ornithine to citrulline.

    '
  inheritance:
  - name: X-linked inheritance
    evidence:
    - reference: PMID:31110235
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
      explanation: Supports inherited enzymatic defects as the basis of UCDs; OTC is X-linked.
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ornithine transcarbamylase are present in the mitochondrial matrix
    explanation: Confirms OTC localization and its role in the urea cycle.
- name: Carbamoyl phosphate synthetase I (CPS1) deficiency
  features: 'CPS1 catalyzes the first committed step of the urea cycle in the mitochondrial matrix, converting ammonia and
    bicarbonate to carbamoyl phosphate. Deficiency causes severe neonatal hyperammonemia. CPS1 requires N-acetylglutamate
    (NAG) as an obligate allosteric activator.

    '
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
      explanation: Supports congenital enzymatic defects as the genetic basis.
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix
    explanation: Directly identifies CPS1 as a mitochondrial urea cycle enzyme.
- name: Argininosuccinate synthetase (ASS1) deficiency
  features: 'ASS1 deficiency causes citrullinemia type I. ASS1 catalyzes the cytosolic condensation of citrulline and aspartate
    to form argininosuccinate. Deficiency results in marked elevation of plasma citrulline and variable hyperammonemia.

    '
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm
      explanation: Confirms ASS1 as a cytosolic urea cycle enzyme with congenital deficiency.
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm
    explanation: Directly identifies ASS1 as a cytosolic urea cycle enzyme.
- name: Argininosuccinate lyase (ASL) deficiency
  features: 'ASL deficiency causes argininosuccinic aciduria. ASL cleaves argininosuccinate to arginine and fumarate. Beyond
    hyperammonemia, ASL deficiency has systemic manifestations including chronic liver disease via glutathione dysregulation,
    nitric oxide deficiency, and neurocognitive deficits that are independent of ammonia levels.

    '
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
      explanation: Supports congenital enzymatic defects as the genetic basis.
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm
    explanation: Directly identifies ASL as a cytosolic urea cycle enzyme.
- name: Arginase 1 (ARG1) deficiency
  features: 'ARG1 deficiency (argininemia) is distinct from other UCDs, often presenting with progressive spastic diplegia
    rather than typical hyperammonemic crises. ARG1 hydrolyzes arginine to ornithine and urea in the final step of the urea
    cycle. Elevated arginine and guanidino compounds are thought to contribute to the spasticity phenotype.

    '
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
      explanation: Supports congenital enzymatic defects as the genetic basis.
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: arginase 1) are present in the cytoplasm
    explanation: Identifies ARG1 as a cytosolic urea cycle enzyme.
- name: N-Acetylglutamate synthase (NAGS) deficiency
  features: 'NAGS produces N-acetylglutamate, the obligate allosteric activator of CPS1. NAGS deficiency phenocopies CPS1
    deficiency with severe neonatal hyperammonemia. Uniquely among UCDs, NAGS deficiency is treatable with carglumic acid,
    a synthetic NAG analog that directly activates CPS1.

    '
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function.
      explanation: Confirms NAGS as essential to urea cycle function.
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function.
    explanation: Directly identifies NAGS as essential for urea cycle function.
treatments:
- name: Protein-restricted diet
  description: 'Controlled protein intake to reduce nitrogen load while preserving growth is the cornerstone of chronic UCD
    management. Natural protein is limited and supplemented with essential amino acid mixtures to maintain adequate nutrition
    and growth.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:30982989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: even while effective therapies do exist
    explanation: Supports the existence of effective therapeutic management including dietary therapy.
- name: Nitrogen scavenger therapy
  description: 'Sodium phenylbutyrate is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine,
    providing an alternative renal route for waste nitrogen excretion. Glycerol phenylbutyrate is a newer palatable formulation.
    Sodium benzoate conjugates with glycine to form hippurate for renal excretion.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We review here the current concepts of the pathogenesis, diagnostics, including genetics and treatment of UCDs.
    explanation: Supports nitrogen scavenger therapy as part of standard UCD treatment.
- name: Arginine and citrulline supplementation
  description: 'Arginine supplementation replaces the amino acid that cannot be synthesized endogenously in most UCDs (except
    ARG1 deficiency). Citrulline supplementation may be preferable as it bypasses intestinal and hepatic first-pass metabolism
    and has been associated with lower mean ammonia concentrations compared to arginine alone.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Severity and age of onset depend on residual enzyme or transporter function and are related to the respective
      gene mutations.
    explanation: Enzyme-specific deficits require targeted amino acid supplementation.
  notes: 'Citrulline supplementation was associated with mean ammonia of 35.9 umol/L versus 49.8 umol/L with arginine in a
    retrospective cohort. Arginine is contraindicated in ARG1 deficiency.

    '
- name: Carglumic acid
  description: 'Carglumic acid (Carbaglu) is a synthetic analog of N-acetylglutamate that directly activates CPS1. It is specifically
    indicated for NAGS deficiency and is also used for hyperammonemia in organic acidemias. It provides pharmacological bypass
    of the NAGS enzyme deficiency.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function.
    explanation: NAGS produces the obligate CPS1 activator; carglumic acid replaces this function.
- name: Acute hyperammonemia management
  description: 'Emergency management includes cessation of protein intake, high-calorie glucose infusion to reverse catabolism,
    intravenous nitrogen scavengers (sodium benzoate, sodium phenylacetate), and arginine supplementation. When ammonia exceeds
    500 umol/L or encephalopathy is present, extracorporeal clearance with continuous renal replacement therapy (CRRT) is
    recommended.

    '
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain.
    explanation: Supports urgent ammonia-lowering treatment during crises.
- name: Liver transplantation
  description: 'Liver transplantation remains the only curative option for severe UCDs, restoring full urea cycle capacity.
    It is indicated for patients with recurrent severe hyperammonemic crises despite maximal medical therapy. Benefits include
    elimination of hyperammonemia risk, dietary liberalization, and improved quality of life, but carry lifelong immunosuppression
    requirements.

    '
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
  evidence:
  - reference: PMID:30982989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: even while effective therapies do exist
    explanation: Supports liver transplantation as an effective definitive therapy.
- name: Newborn screening
  description: 'Some UCDs are detectable through expanded newborn screening by tandem mass spectrometry. Citrullinemia type
    I (elevated citrulline) and ASL deficiency (elevated argininosuccinic acid) are most reliably detected. Early identification
    enables pre-symptomatic treatment initiation and prevention of neonatal crises.

    '
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:30982989
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: experience on newborn screening for some UCDs has widened
    explanation: Confirms expanding newborn screening programs for UCD detection.
- name: Genetic counseling
  description: 'Genetic counseling for affected families, including discussion of inheritance patterns (autosomal recessive
    for most UCDs, X-linked for OTC deficiency), recurrence risk assessment, carrier testing, and prenatal or preimplantation
    genetic diagnosis options.

    '
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Severity and age of onset depend on residual enzyme or transporter function and are related to the respective
      gene mutations.
    explanation: Genotype-phenotype correlations support the importance of genetic counseling.
progression:
- notes: 'Disease progression follows a characteristic pattern: (1) inherited enzyme/transporter deficiency reduces hepatic
    ureagenesis capacity; (2) catabolic triggers (infection, fasting, surgery, protein loading) precipitate ammonia accumulation;
    (3) ammonia crosses the blood-brain barrier and is converted to glutamine in astrocytes, driving osmotic swelling and
    cerebral edema; (4) encephalopathy, seizures, and neurological injury develop if ammonia is not rapidly controlled. Chronic
    complications include progressive intellectual disability, movement disorders, and in some subtypes (ASL deficiency),
    liver disease. Late-onset forms may remain undiagnosed until adulthood, presenting during windows of physiological stress.'
environmental:
- name: Catabolic stress triggers
  description: 'Intercurrent illness, fasting, surgery, high protein intake, and medications such as valproate can precipitate
    hyperammonemic crises by increasing endogenous protein catabolism and nitrogen load beyond the impaired ureagenesis capacity.

    '
  evidence:
  - reference: PMID:37938118
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Mild UCDs presenting in adulthood are increasingly recognized, so broader screening in adults is recommended.
    explanation: Late-onset UCD presentations during physiologic stress support the role of environmental triggers.
references:
- reference: DOI:10.1002/jimd.12609
  findings: []
- reference: DOI:10.1002/jimd.12807
  findings: []
- reference: DOI:10.1007/s11604-023-01396-0
  findings: []
- reference: DOI:10.1016/j.pediatrneurol.2024.06.013
  findings: []
- reference: DOI:10.1126/scitranslmed.adh1334
  findings: []
- reference: DOI:10.1186/s13023-023-02800-8
  findings: []
- reference: DOI:10.1186/s13023-025-03625-3
  findings: []
- reference: DOI:10.3390/app14041647
  findings: []
- reference: DOI:10.3390/biom13020396
  findings: []
- reference: DOI:10.3390/metabo15070446
  findings: []
- reference: DOI:10.3390/metabo15090573
  findings: []
- reference: DOI:10.3390/nu16010013
  findings: []
notes: 'UCDs are a heterogeneous group with incidence of approximately 1 in 35,000 births. The 2019 revised European guidelines
  (PMID:30982989) remain the primary reference for diagnosis and management. Key advances include quantitative seizure risk
  modeling showing 2.65-fold increased odds per 100 umol/L ammonia (PMID:39121557), identification of glutathione dysregulation
  in ASL deficiency, and development of gene and mRNA therapy approaches. OTC deficiency is the most common subtype, accounting
  for approximately 50% of cases. Adult-onset presentations during catabolic stress are increasingly recognized. The field
  is moving toward hepatocyte-targeted gene and RNA therapies, though liver transplantation remains the only curative option
  currently available.

  '
